Stay informed about health news and updates in Philadelphia, PA.
A clinical trial has shown that Lenacapavir, a twice-yearly injectable form of PrEP, reduced HIV infections by 96%, outperforming daily oral PrEP options. Gilead is seeking FDA approval for Lenacapavir for PrEP use, with hopes for a market launch by mid to late 2025. This advancement could significantly improve HIV prevention strategies.
A clinical trial has shown that Lenacapavir, a twice-yearly injectable form of PrEP, significantly reduces HIV infections by 96%, outperforming the daily pill option. Gilead Sciences aims to gain FDA approval for Lenacapavir as a preventive measure against HIV, with potential market availability by mid-2025.
Malecare, a non-profit organization, has been a vital support system for gay men facing prostate cancer for over two decades. Founded by oncology social worker Darryl Mitteldorf, the organization emphasizes patient empowerment and community support, particularly highlighting the unique challenges faced by gay men in navigating their health. As Prostate Cancer Awareness Month approaches, Mitteldorf discusses the evolving landscape of care and the importance of peer support.
Malecare provides crucial peer-to-peer support and advocacy for gay men dealing with prostate cancer, emphasizing patient empowerment in medical care. Founded by Darryl Mitteldorf in 1998, the non-profit has adapted to changes in healthcare dynamics, especially post-COVID, to enhance patient engagement and education.